Literature DB >> 20889971

Thrombin inhibition by serpins disrupts exosite II.

Wei Li1, Daniel J D Johnson, Ty E Adams, Nicola Pozzi, Vincenzo De Filippis, James A Huntington.   

Abstract

Thrombin uses three principal sites, the active site, exosite I, and exosite II, for recognition of its many cofactors and substrates. It is synthesized in the zymogen form, prothrombin, and its activation at the end of the blood coagulation cascade results in the formation of the active site and exosite I and the exposure of exosite II. The physiological inhibitors of thrombin are all serpins, whose mechanism involves significant conformational change in both serpin and protease. It has been shown that the formation of the thrombin-serpin final complex disorders the active site and exosite I of thrombin, but exosite II is thought to remain functional. It has also been hypothesized that thrombin contains a receptor-binding site that is exposed upon final complex formation. The position of this cryptic site may depend on the regions of thrombin unfolded by serpin complexation. Here we investigate the conformation of thrombin in its final complex with serpins and find that in addition to exosite I, exosite II is also disordered, as reflected by a loss of affinity for the γ'-peptide of fibrinogen and for heparin and by susceptibility to limited proteolysis. This disordering of exosite II occurs for all tested natural thrombin-inhibiting serpins. Our data suggest a novel framework for understanding serpin function, especially with respect to thrombin inhibition, where serpins functionally "rezymogenize" proteases to ensure complete loss of activity and cofactor binding.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20889971      PMCID: PMC2992294          DOI: 10.1074/jbc.M110.144964

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  The serpin inhibitory mechanism is critically dependent on the length of the reactive center loop.

Authors:  A Zhou; R W Carrell; J A Huntington
Journal:  J Biol Chem       Date:  2001-04-26       Impact factor: 5.157

2.  The pH dependence of serpin-proteinase complex dissociation reveals a mechanism of complex stabilization involving inactive and active conformational states of the proteinase which are perturbable by calcium.

Authors:  S V Calugaru; R Swanson; S T Olson
Journal:  J Biol Chem       Date:  2001-06-12       Impact factor: 5.157

Review 3.  Serpin structure, mechanism, and function.

Authors:  Peter G W Gettins
Journal:  Chem Rev       Date:  2002-12       Impact factor: 60.622

Review 4.  Diverse role of LDL receptor-related protein in the clearance of proteases and in signaling.

Authors:  D K Strickland; S Ranganathan
Journal:  J Thromb Haemost       Date:  2003-07       Impact factor: 5.824

5.  Fibrinogen gamma' chain binds thrombin exosite II.

Authors:  R S Lovely; M Moaddel; D H Farrell
Journal:  J Thromb Haemost       Date:  2003-01       Impact factor: 5.824

6.  Crystal structure of bovine trypsinogen at 1-8 A resolution. II. Crystallographic refinement, refined crystal structure and comparison with bovine trypsin.

Authors:  H Fehlhammer; W Bode; R Huber
Journal:  J Mol Biol       Date:  1977-04-25       Impact factor: 5.469

7.  A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.

Authors:  R Egelund; T E Petersen; P A Andreasen
Journal:  Eur J Biochem       Date:  2001-02

8.  Insight into the mechanism of serpin-proteinase inhibition from 2D [1H-15N] NMR studies of the 69 kDa alpha 1-proteinase inhibitor Pittsburgh-trypsin covalent complex.

Authors:  F C Peterson; P G Gettins
Journal:  Biochemistry       Date:  2001-05-29       Impact factor: 3.162

9.  Conformational changes in thrombin when complexed by serpins.

Authors:  J C Fredenburgh; A R Stafford; J I Weitz
Journal:  J Biol Chem       Date:  2001-10-02       Impact factor: 5.157

10.  Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human PPACK-thrombin.

Authors:  R K Arni; K Padmanabhan; K P Padmanabhan; T P Wu; A Tulinsky
Journal:  Biochemistry       Date:  1993-05-11       Impact factor: 3.162

View more
  7 in total

1.  Novel heparin mimetics reveal cooperativity between exosite 2 and sodium-binding site of thrombin.

Authors:  May H Abdel Aziz; Umesh R Desai
Journal:  Thromb Res       Date:  2018-03-17       Impact factor: 3.944

2.  Rational design of potent, small, synthetic allosteric inhibitors of thrombin.

Authors:  Preetpal Singh Sidhu; Aiye Liang; Akul Y Mehta; May H Abdel Aziz; Qibing Zhou; Umesh R Desai
Journal:  J Med Chem       Date:  2011-07-18       Impact factor: 7.446

3.  Non-canonical proteolytic activation of human prothrombin by subtilisin from Bacillus subtilis may shift the procoagulant-anticoagulant equilibrium toward thrombosis.

Authors:  Giulia Pontarollo; Laura Acquasaliente; Daniele Peterle; Roberta Frasson; Ilaria Artusi; Vincenzo De Filippis
Journal:  J Biol Chem       Date:  2017-07-06       Impact factor: 5.157

4.  Exogenous human α-Synuclein acts in vitro as a mild platelet antiaggregant inhibiting α-thrombin-induced platelet activation.

Authors:  Laura Acquasaliente; Giulia Pontarollo; Claudia Maria Radu; Daniele Peterle; Ilaria Artusi; Anna Pagotto; Federico Uliana; Alessandro Negro; Paolo Simioni; Vincenzo De Filippis
Journal:  Sci Rep       Date:  2022-06-14       Impact factor: 4.996

5.  Ligand binding to anion-binding exosites regulates conformational properties of thrombin.

Authors:  Marina V Malovichko; T Michael Sabo; Muriel C Maurer
Journal:  J Biol Chem       Date:  2013-02-01       Impact factor: 5.157

6.  Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function.

Authors:  Calvin H Yeh; Alan R Stafford; Beverly A Leslie; James C Fredenburgh; Jeffrey I Weitz
Journal:  PLoS One       Date:  2016-06-15       Impact factor: 3.240

7.  The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand.

Authors:  Amanda J Boyle; Leigh Ann Roddick; Varsha Bhakta; Melissa D Lambourne; Murray S Junop; Patricia C Liaw; Jeffrey I Weitz; William P Sheffield
Journal:  BMC Biochem       Date:  2013-03-07       Impact factor: 4.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.